

**Stichting European Uro-Oncology Group (EUOG)**  
**Zernikedreef 8**  
**2333 CL LEIDEN**

**ANNUAL REPORT 2020**



<b>TABLE OF CONTENTS</b>	<b>Blz.</b>
<b>Report of the auditors</b>	
<b><u>Accountant's compilation report</u></b>	
Financial position	3
<b><u>Management board's report</u></b>	
<b><u>Financial Statements 2020</u></b>	
Balance sheet as at 31 December 2020	10
Profit & loss account for the year 2020	12
Notes to the financial statements	13
Notes to various items on the balance sheet	14
Off balance sheet commitments	16
(proposition to) appropriation of the positive / negative balance	16
Events subsequent to the balance sheet date	16
Notes to the profit and loss account	17
Adoption of the financial statements	19
<b><u>Other information</u></b>	

## ACCOUNTANTSREPORT

To the board of  
Stichting European Uro-oncology Group  
Zernikedreef 8  
2333 CL LEIDEN

June 30, 2021

Dear members of the board,

Hereby we report to you the financial statements 2020 of your foundation. The balance sheet at December 31, 2020, the profit and loss account for 2020 and the notes, which together constitute the financial statements, as well as other information have been included in this report.

### ACCOUNTANT'S COMPILATION REPORT

The financial statements of Stichting European Uro-oncology Group based in Leiden have been compiled by us using the information provided by you. The financial statements comprise the balance sheet as at 31 December 2020 and the profit and loss account for the year 2020, with the accompanying explanatory notes. These notes include a summary of the accounting policies which have been applied.

This compilation engagement has been performed by us in accordance with Dutch law, including the Dutch Standard 4410, 'Compilation engagements', which is applicable to accountants. The standard requires us to assist you in the preparation and presentation of the financial statements in accordance with Part 9 of Book 2 of the Dutch Civil Code. To this end we have applied our professional expertise in accounting and financial reporting.

In a compilation engagement, you are responsible for ensuring that you provide us with all relevant information and that this information is correct. Therefore, we have conducted our work, in accordance with the applicable regulations, on the assumption that you have fulfilled your responsibility. To conclude our work, we have read the financial statements as a whole to consider whether the financial statements as presented correspond with our understanding of Stichting European Uro-oncology Group. We have not performed any audit or review procedures which would enable us to express an opinion or a conclusion as to the fair presentation of the financial statements.

During this engagement we have complied with the relevant ethical requirements prescribed by the 'Verordening Gedrags- en Beroepsregels Accountants' (VGBA, Dutch Code of Ethics). You and other users of these financial statements may therefore assume that we have conducted the engagement in a professional, competent and objective manner and with due care and integrity and that we will treat all information provided to us as confidential.



## FINANCIAL POSITION

### Result

The result over the financial year is -/- € 119.107 relative to a result over 2019 of € 1.821.806.

### Result comparison

To analyze the result of the foundation, we provide you with the following statement, which is based on the statement of profit and loss of the foundation.

	<b>2020</b>		<b>2019</b>	
	<b>x € 1</b>	<b>in %</b>	<b>x € 1</b>	<b>in %</b>
<b>Profits</b>				
Grants profits	42.326	100	88.500	4
Profits	0	0	0	0
Financial income and expenses	<u>0</u>	<u>0</u>	<u>1.982.060</u>	<u>96</u>
<b>Profits</b>	<u>42.326</u>	<u>100</u>	<u>2.070.560</u>	<u>100</u>
Research costs LUMC	71.117	39	141.357	57
Wage and salaries	93.768	52	93.206	38
Depreciation of fixed assets	0	0	0	0
Other personnel expenses	0	0	0	0
Accommodation expenses	0	0	326	0
Inventory expenses	0	0	0	0
Transportation expenses	0	0	0	0
Promotion expenses	0	0	0	0
General expenses	15.545	9	13.865	5
<b>Total costs</b>	<u>180.430</u>	<u>100</u>	<u>248.754</u>	<u>100</u>
<b>Financial income and expenses</b>	<u>-18.997</u>		<u>0</u>	
<b>Result</b>	<u>-119.107</u>		<u>1.821.806</u>	

### Finance overview

The following analysis is based on the data from the balance sheet to analyze the financial position.

	<b>31-12-20</b>	<b>31-12-19</b>
Short-term basis:		
Cash and cash equivalents	1.893.965	2.002.398
Receivables	<u>0</u>	<u>30.000</u>
	1.893.965	2.032.398
Minus: short-term liabilities	<u>43.820</u>	<u>63.146</u>
Working capital	1.850.145	1.969.252
Long-term basis:		
Tangible fixed assets	<u>0</u>	<u>0</u>
Funded with long term available resources	<u>0</u>	<u>0</u>
This finance is made possible with:		
Foundation capital	1.850.145	1.969.252
Long-term liabilities	<u>0</u>	<u>0</u>
	<u>1.850.145</u>	<u>1.969.252</u>

### Liquidity

Some further insight into the liquidity is provided in the numbers below.

	<b>2020</b>	<b>2019</b>
Cash and cash equivalents as at 31 December	1.893.965	2.002.398
Cash and cash equivalents as at 1 January	<u>2.002.398</u>	<u>242.825</u>
Increase (+)/decrease (-) cash/ cash equivalents	<u>108.433</u>	<u>1.759.573</u>

The explanation for this increase can be found in the cash flow statement below, compiled according to the indirect method.

<b>Cash flow statement</b>	<b>2020</b>	<b>2019</b>
<b>Cash flow from operational activities</b>		
Result	-119.107	1.821.806
Plus: depreciation	<u>0</u>	<u>0</u>
<b>Cash flow</b>	<b>-119.107</b>	<b>1.821.806</b>
<b>Mutations in working capital (excluding cash and cash equivalents)</b>		
Increase /decrease receivables	30.000	-30.000
Decrease of current liabilities	<u>-19.326</u>	<u>-32.233</u>
	<u>10.674</u>	<u>-67.233</u>
	-108.433	1.759.573
<b>Cash flow from investing activities</b>		
Investments	0	0
Divestments	<u>0</u>	<u>0</u>
	<u>0</u>	<u>0</u>
	0	0
<b>Cash flow from financing activities</b>		
Added loans	0	0
Repaid loans	<u>0</u>	<u>0</u>
	<u>0</u>	<u>0</u>
Increase cash and cash equivalents	<u>-108.433</u>	<u>1.759.573</u>

The positive amounts in the cash flow statement increase liquidity (source of funds). The negative amounts impose liquidity (use of funds).

**Signature**

We trust to have been of service. Should you have any questions or comments, we are available to provide a more detailed explanation

Sincerely,

Leiden, June 30, 2021

Bunnig & Partners Accountants + Adviseurs B.V.

w.g.  
drs. P. Timmermans RA

## Report 2020 of the Board of the EUOG

### General

The Board has met twice in 2020 on 3 June 2020 and on 16 December by videoconference due to the COVID limitations. Present: Mr. L. Beckers, Mr. I.J. de Jong, Mr. W. Loidl, Mr. H. van Poppel, Mrs. S. Osanto

Because of the 2020 WNRA law, Trial Office staff has subsequently been employed directly by the EUOG Foundation. Mrs. Alvarez was appointed as manager of the EUOG Clinical Trial Office.

In December 2020 Mr. Beckers retired from the board.

During the meeting in June the Board discussed the need for a business plan for the next 5-10 years. To this purpose, a presentation was prepared and discussed during the June Board meeting.

Information about EUOG's mission in 2021 and beyond and strategy and -in accordance with requirements for the ANBI status (non-profit, charity foundation)- the annual report can be found on the website [www.euog.org](http://www.euog.org).

The financial statements have been prepared by Bunnig & Partners Accountants in Leiden in cooperation with the EUOG Foundation.

### Research

There are 3 EUOG studies in progress, a 4th study for 'intravenous liposomal dexamethasone in patients with metastatic prostate cancer', co-developed by EUOG has recently been finalized.

Two studies investigate the clinical utility of WB MRI and PET CT scan in patients with hormone-sensitive metastatic prostate cancer ("HORNA study") or chemotherapy-naïve metastatic castration-resistant prostate cancer ("CHENA study") undergoing enzalutamide treatment. The target number of patients has been reached for HORNA and the CHENA study is ongoing.

The URANUS study explores feasibility, efficacy and outcome in patients with upper urinary tract urothelial cell carcinoma (UTUC) scheduled to undergo surgery, who are randomized to neoadjuvant or adjuvant chemotherapy, or undergo surgery alone when unfit for chemotherapy. The trial is in progress. The trial has been approved for Spain by the Medical Agencies and METC. Visiting centers in Spain was interrupted because of the COVID pandemic. A considerable number of centers in Spain were acquired in 2020 (n=22), agreements prepared, by October the first initiation visits could be done and centers activated.

The expansion of centers for this study in such a rare disease has resulted in a considerable increase in workload for the EUOG trial office in 2020.

An Upper Tract Urothelial Carcinoma (UTUC) International Collaborative Database Consortium (UICD) investigating prediction models and across countries outcome differences is ongoing. Dedicated members convene regularly. Further expansion to other continents for the global consortium is being pursued.

### Financial report

The revenues in 2020 were partially coming from grants, among others from Astellas.

The expenses of the EUOG Foundation were for daily operational costs, as salaries, insurances, juridical and accountant expenses. Furthermore, the foundation has paid substantial amounts for reimbursement to participating hospitals in studies to compensate expenses as agreed upon.

The balance on the bank accounts was on December 31, 2020 € 1.893.965.



## **Conclusion**

The Foundation has made progress in ongoing studies and participation by more members from different centers and countries is being realized. Its portfolio has been enlarged and underscores broad interest and support to participate in urological cancer studies. The Foundation contributes to cancer research through Europe and beyond, with the aim to find new and better solutions for cancer patients. To make this possible and to continue these activities, the Foundation is striving to obtain grants, donations and gifts.

Leiden, June 28, 2021 signed

Chairman, S. Osanto (on behalf of the entire board)

Secretary-Treasurer, I.J. de Jong (agreed during the board meeting)

Board member, W. Loidl (agreed during the board meeting)

Board member, H. van Poppel (agreed during the board meeting)

**FINANCIAL STATEMENTS 2020**  
**OF**  
**STICHTING EUROPEAN URO-ONCOLOGY GROUP**



**BALANCE as at December 31 2020**

---

<b>ASSETS</b>	<b>31-12-2020</b>	<b>31-12-2019</b>
	€	€
<b>Fixed assets</b>		
Tangible fixed assts:		
Inventory	0	0
Means of transport	<u>0</u>	<u>0</u>
	0	0
<b>Current assets</b>		
Debtors	0	0
Taxes and social securities	0	0
Other receivables (1)	0	30.000
Cash and cash equivalents (2)	<u>1.893.965</u>	<u>2.002.398</u>
	1.893.965	2.032.398
<b>Total assets</b>	<u><u>1.893.965</u></u>	<u><u>2.032.398</u></u>

**of Stichting European Uro-Oncology Group** **after determination of the result**

<b>EQUITY AND LIABILITIES</b>	<b>31-12-2020</b>	<b>31-12-2019</b>
	<b>€</b>	<b>€</b>
<b>Foundation capital</b>		
Designated reserve (3)	1.850.145	1.969.252
<b>Current liabilities</b>		
Taxes and social securities	0	0
Creditors (4)	12.436	2.183
Other liabilities (5)	<u>31.384</u>	<u>60.963</u>
	43.820	63.146
<b>Total equity and liabilities</b>	<u><u>1.893.965</u></u>	<u><u>2.032.398</u></u>

**PROFIT & LOSS ACCOUNT FOR THE YEAR 2020**

		<b>Realization 2020 €</b>	<b>Realization 2019 €</b>
<b>PROFITS</b>			
Grants/subsidy	(6)	42.326	88.500
Other profits		0	1.982.060
<b>Sum of profits</b>		<u>42.326</u>	<u>2.070.560</u>
<b>EXPENSES</b>			
Research costs	(7)	71.117	141.357
Wages and salaries	(8)	93.768	93.206
Other expenses	(9)	15.545	14.191
<b>Sum of expenses</b>		<u>180.430</u>	<u>248.754</u>
<b>Financial income and expenses</b>			
Investment results		<u>18.997</u>	<u>0</u>
<b>Result</b>		<u>-119.107</u>	<u>1.821.806</u>

## **NOTES TO THE FINANCIAL STATEMENTS**

Statutory name: Stichting European Uro-Oncology Group

Registered address: Leiden

### **Principles of valuation**

#### **General**

The financial statements have been prepared in accordance with the provisions of the Annual Reporting Guideline "C1 Small Organizations-Without-Profit"

The financial statements of the company are presented in euros, which is the company's functional currency. Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are presented at nominal value.

The income and expenses are accounted for in the period to which they relate. Obligations and possible expenses that originate before the end of the reporting year are taken into account if and insofar as they have become known before the preparation of the financial statements. Depreciation of fixed assets is based on the acquisition value. Depreciation takes place according to the straight-line method based on the estimated economic life.

### **PRINCIPLES OF VALUATION OF ASSETS AND LIABILITIES**

#### **Trade and other receivables**

The receivables are initially valued at its fair value, and subsequently valued at amortised cost, which is similar to the face value, after deduction of any provisions if necessary.

#### **Cash and cash equivalents**

Cash and cash equivalents are valued at nominal value.

#### **Liabilities**

Current liabilities are initially valued at its fair value, and subsequently valued at amortised cost, which is similar to the face value. Accruals are valued at its face value.

### **PRINCIPLES FOR THE DETERMINATION OF THE RESULT**

#### **General**

The result is defined as the difference between the profits on one hand and on the other hand the costs and expenses for that year, valued at historical costs. They are determined in accordance with the aforementioned valuation principles. Profits are recognized in the year in which the goods were delivered or the services rendered. Losses originating in the financial year are taken into account as soon as they are foreseeable.

#### **Grants/subsidy**

Grants are recognized as income in the statement of profits & loss in the year in which the subsidized costs were incurred or revenues were lost, or when a subsidized operating deficit occurred. The subsidy recognized when it is probable that it will be received.

**NOTES TO VARIOUS ITEMS ON THE BALANCE SHEET**

**ASSETS**

<b>1. Trade and other receivables</b>	<b>31-12-20</b>	<b>31-12-19</b>
	<b>€</b>	<b>€</b>
Receivable grants	0	30.000
Other prepaid costs	0	0
	<u>0</u>	<u>30.000</u>
 <b>2. Cash and cash equivalents</b>		
Cash	0	0
Van Lanschot, account .247	0	0
Rabobank, account .07	72.908	200.338
KBC Cash	35.705	24.230
KBC Portfolio	1.785.352	1.777.830
	<u>1.893.965</u>	<u>2.002.398</u>

The cash and cash equivalents are freely available to the foundation.

**EQUITY AND LIABILITIES**

**Foundation capital**

**3. Foundation capital**

**Designated reserve**

The mutations are as follows:

	<b>2020</b>	<b>2019</b>
	<b>€</b>	<b>€</b>
Balance as at 1 January	1.969.252	147.446
Mutation	-119.107	1.821.806
Balance as at 31 December	<u>1.850.145</u>	<u>1.969.252</u>

The designated reserve of Stichting EUOG originated from the grants received from various parties and is exclusively intended for the prescribed research.

**Current liabilities**

**4. Creditors**

In accordance with declaration	<u>12.436</u>	<u>2.183</u>
--------------------------------	---------------	--------------

**5. Accrued liabilities**

Invoices yet to be received LUMC	21.050	51.701
Liabilities Uranus Study	0	5.262
Accounting and administration fee	4.000	4.000
Other liabilities	6.334	-
	<u>31.384</u>	<u>60.963</u>



## **OFF-BALANCE SHEET COMMITMENTS**

## **OTHER EXPLANATORY NOTES**

### **Proposition to appropriation of the positive / negative balance**

The board proposes to add the result to the freely available capital of the foundation by means of an addition to the foundation capital.

### **Events with financial consequences subsequent to the balance sheet date**

There have been no events affecting this report between the balance sheet date and the time of drawing up the balance sheet.

**NOTES TO THE PROFIT AND LOSS ACCOUNT**

	<b>Realization 2020</b>	<b>Realization 2019</b>
	€	€
<b>PROFITS</b>		
<b>6. GRANTS</b>		
Grant Astellas 04	39.000	58.500
Study fee Intravenous liposomal dexamethasone (*)	0	30.000
European Uro-Oncology Group Belgium (**)	0	1.982.060
Other grants	3.326	0
	<u>42.326</u>	<u>2.070.560</u>

(\*) Reimbursement of operational costs for participation in the study Intravenous liposomal dexamethasone in patients with metastatic prostate cancer.

(\*\*) In 2019 an associated non-profit organization (I VZW) in Belgium with similar research aims and objectives, ceased to exist; by valid decision under the liquidation procedure of this NGO, the available cash balances and securities portfolio were transferred to the EUOG, while maintaining the existing banking relationship of the former VZW.

**7. Research costs LUMC**

Research costs LUMC, CHENA Material costs	14.766	41.312
Research costs LUMC, CHENA Personnel costs	1.430	7.010
Research costs LUMC, HORNA Material costs	39.495	73.363
Research costs LUMC, HORNA Personnel costs	2.157	7.010
Costs, Uranus Study	13.269	12.662
	<u>71.117</u>	<u>141.357</u>

**Lasten**

	<b>Realization 2020</b>	<b>Realization 2019</b>
	€	€
<b>8. Wage and salaries</b>		
Hiring staff LUMC Trial Office	25.747	93.206
Wage and salaries	68.021	0
	<u>93.768</u>	<u>93.206</u>

	<b>Realisatie 2020</b>	<b>Realisatie 2019</b>
	€	€
<b>9. Other expenses</b>		
Accommodation expenses	0	326
Small expenses	537	0
Selling expenses	2.012	1.886
General expenses	12.996	11.979
	<u>15.545</u>	<u>14.191</u>
<i>Selling expenses</i>		
Travel and accommodation	1.622	846
Conference costs	0	605
Promotional gifts	390	170
Dinners	0	247
Printed brochures	0	18
	<u>2.012</u>	<u>1.886</u>
<i>General expenses</i>		
Other general expenses	0	0
Accounting and administration fee	5.474	4.085
Other consultancy charges	6.245	5.813
Telephonedcosts	147	402
IT costs	0	920
Office costs	227	0
Insurances	766	609
Bank charges	192	150
Payment and rounding differences	-55	0
	<u>12.996</u>	<u>11.979</u>
<b>10. Financial income and expenses</b>		
Investment results	18.997	0

### **Adoption of the financial statements**

The board of Stichting European Uro-Oncolgy Group based in Leiden hereby declares that it has adopted the financial statements for the 2020 financial year.

Leiden, June 30, 2021

signed

Chair, S. van Dissel - Osanto

(on behalf of the entire board)

Treasurer/secretary, I.J. de Jong

(agreed during the board meeting)

Board member, W. Loidl

(agreed during the board meeting)

Board member, H. van Poppel

(agreed during the board meeting)

# Standaardformulier publicatieplicht ANBI Algemeen

## 1 Algemene gegevens instelling

Naam

Nummer Kamer van  
Koophandel

**Contactgegevens.** Vul minimaal 1 van de velden Adres, Telefoonnummer of E-mailadres in.

Adres

Telefoonnummer

E-mailadres

Website (\*)

RSIN (\*\*)

Actief in sector (\*)

In welke landen is  
uw instelling actief? (\*)

Aantal medewerkers (\*)

Betaalde personeelsleden in gemiddeld aantal fte gedurende het boekjaar.

Aantal vrijwilligers (\*)

Vrijwilligers die zich regelmatig (meer dan 3 keer per jaar) inzetten voor uw instelling.

### Statutair bestuur van de instelling

Voorzitter

Secretaris

Penningmeester

Algemeen bestuurslid

Algemeen bestuurslid

Overige informatie  
bestuur (\*)

Doelgroepen (\*)  
(meerdere opties mogelijk)

Algemeen publiek  
Alleenstaande ouders  
Analfabeten  
Chronisch zieken  
Dak- en thuislozen  
Dieren  
Gedetineerden  
Gelovigen  
Gemeenschappen  
Jongeren

Kinderen  
Lhbtqi+  
Mensen met een beperking  
Milieu  
Minderheden  
Minima  
Natuurgebieden  
Oceanen en zeeën  
Ouderen  
Patiënten

Slachtoffers van geweld  
Slachtoffers van natuurrampen  
Slachtoffers van oorlog  
Slachtoffers van seksueel misbruik  
Studenten  
Verslaafden  
Vluchtelingen  
Vrouwen en meisjes  
Werklozen  
Wildlife  
Overig

(\*) Optioneel veld, niet verplicht

(\*\*) Buiten Nederland gevestigde instellingen moeten het RSIN-nummer verplicht invullen









**Baten**

Baten als tegenprestatie voor levering van producten en/of diensten (omzet)

€

€

Subsidies van overheden

€

€

Subsidies van andere instellingen zonder winststreven

€

€

Overige subsidies

€

€

+

+

**Baten van subsidies**

€

€

Baten sponsorbijdragen

€

€

Giften en donaties van particulieren

€

€

Nalatenschappen

€

€

Bijdragen van loterijinstellingen

€

€

Overige giften

€

€

+

+

**Giften**

€

€

Financiële baten

€

€

Overige baten

€

€

+

+

**Som van de baten**

€

€

**Lasten**

Inkoopwaarde van geleverde producten (kostprijs)

€

€

Verstrekke subsidies &amp; giften

€

€

Aankopen en verwervingen

€

€

Communicatiekosten

€

€

Personeelskosten

€

€

Huisvestingskosten

€

€

Afschrijvingen

€

€

Financiële lasten

€

€

Overige lasten

€

€

+

+

**Som van de lasten**

€

€

**Saldo van baten en lasten**

€

€

